Alligator Bioscience strengthens its FIND® patent portfolio
Lund, November 9, 2007 - Alligator Bioscience, the protein optimization company, is
pleased to announce that it has further strengthened its patent portfolio around the FIND®
technology. The patent portfolio was expanded by the grant of yet another patent. The patent
portfolio around the FIND® technology now consists of 16 granted patents and eight pending
applications. Furthermore, the European Patent Office Opposition Division recently rejected
oppositions by Maxygen Inc. and Codexis Inc. in a decision that confirmed the novelty and
inventiveness of the FIND® process which is protected by Alligator’s European patent No. 1
About Alligator Bioscience AB
Alligator Bioscience uses its proprietary FIND® technology to develop new and optimize
existing therapeutic and diagnostic proteins.
Since 2001, Alligator Bioscience has successfully collaborated with several companies in the
pharmaceutical, diagnostic and biotech industry, improving customers’ proteins and helping
them to build more competitive pipelines. The company has also created an internal pipeline
of therapeutic drug candidates for major clinical indications, which are at varying stages of
Alligator Bioscience operates from the Ideon Science Park in Lund, and has 23 employees.
The company has around 150 shareholders.
For further general information please visit www.alligatorbioscience.com.
If you have any questions please contact Dr Gun-Britt Fransson, CEO of Alligator Bioscience
AB, +46 46 286 4284.